Last reviewed · How we verify
NCT05904691
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Phase 1 trial testing OCU-10-C-110 for Injection in Neovascular Age-related Macular Degeneration (nAMD) in 19 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | Ocugenix Corporation |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 1 November 2023 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- OCU-10-C-110 for Injection — full drug profile →
Conditions studied
- Neovascular Age-related Macular Degeneration (nAMD) — all drugs for Neovascular Age-related Macular Degeneration (nAMD) →
Sponsor
Ocugenix Corporation — full company profile →
Who can join
50 and older, any sex, with Neovascular Age-related Macular Degeneration (nAMD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases.
Lin JB, Apte RS. · · 2025 · cited 3× · PMID 39836404 · DOI 10.1167/iovs.66.1.47 -
Safety and Biological Activity of Intravitreal OGX110, a CXCR3 Agonist, in Persistent Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study
Wells A, Boyer D, Goldberg RA, Hohman T, et al · · 2026 · DOI 10.64898/2026.05.21.26353430
Verify or expand the search:
- PubMed search for NCT05904691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neovascular Age-related Macular Degeneration (nAMD)
Currently open trials in the same condition.
- NCT06929143 — A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular · active not recruiting
- NCT06795048 — A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macu · Phase 4 · active not recruiting
- NCT06075147 — The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impair · active not recruiting
- NCT04657289 — A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Rani · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05904691 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ocugenix Corporation
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing